Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the rare neurological condition known as Down Syndrome Regression Disorder (DSRD). Individuals with a DSRD diagnosis often experience symptoms like catatonia or unresponsiveness, loss of speech, loss of ability to perform activities of daily living, hallucinations, delusions, and aggression. DSRD is more common in adolescents and young adults.
In this study, we are researching the safety and efficacy of three potential therapies: lorazepam, intravenous immunoglobulin (IVIG) and tofacitinib.
We will assess two main outcomes: